CL2018000033A1 - Composición para destapar una nariz tapada que tiene actividad antiviral. - Google Patents

Composición para destapar una nariz tapada que tiene actividad antiviral.

Info

Publication number
CL2018000033A1
CL2018000033A1 CL2018000033A CL2018000033A CL2018000033A1 CL 2018000033 A1 CL2018000033 A1 CL 2018000033A1 CL 2018000033 A CL2018000033 A CL 2018000033A CL 2018000033 A CL2018000033 A CL 2018000033A CL 2018000033 A1 CL2018000033 A1 CL 2018000033A1
Authority
CL
Chile
Prior art keywords
composition
uncover
carragenine
ionic
antiviral activity
Prior art date
Application number
CL2018000033A
Other languages
English (en)
Inventor
Andreas Grassauer
Eva Prieschl-Grassauer
Angelika Bodenteich
Martina Morokutti-Kurz
Christiane Koller
Original Assignee
Marinomed Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinomed Biotech Ag filed Critical Marinomed Biotech Ag
Publication of CL2018000033A1 publication Critical patent/CL2018000033A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731Carrageenans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LLA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE TIENE UNA ACTIVIDAD PARA DESTAPAR UNA NARIZ TAPADA, CARACTERIZADA PORQUE LA COMPOSICIÓN COMPRENDE UNA SOLUCIÓN ACUOSA HIPEROSMOLAR DE UN AGENTE DE AJUSTE DE LA OSMOLALIDAD NO IÓNICA, OPCIONALMENTE EN COMBINACIÓN CON UN AGENTE DE AJUSTE DE LA OSMOLALIDAD IÓNICA, DONDE LA COMPOSICIÓN COMPRENDE ADEMÁS IOTA -CARRAGENINA Y / O KAPPA-CARRAGENINA COMO INGREDIENTE ANTIVIRAL ACTIVO EN UNA CANTIDAD ANTIVIRALMENTE EFICAZ, CON LA CONDICIÓN DE QUE LA COMPOSICIÓN EN SU FORMULACIÓN LISTA PARA USAR CONTENGA NO MÁS DE 0 - 1,5% P / V DEL AGENTE DE AJUSTE DE LA OSMOLALIDAD IÓNICA. LA COMPOSICIÓN ES ÚTIL PARA DESTAPAR UNA NARIZ TAPADA Y PARA LA INTERVENCIÓN PROFILÁCTICA O TERAPÉUTICA DE VARIAS INFECCIONES VIRALES DEL TRACTO RESPIRATORIO SUPERIOR.
CL2018000033A 2015-07-14 2018-01-05 Composición para destapar una nariz tapada que tiene actividad antiviral. CL2018000033A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15176670 2015-07-14

Publications (1)

Publication Number Publication Date
CL2018000033A1 true CL2018000033A1 (es) 2018-08-10

Family

ID=53717900

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000033A CL2018000033A1 (es) 2015-07-14 2018-01-05 Composición para destapar una nariz tapada que tiene actividad antiviral.

Country Status (27)

Country Link
US (1) US10660914B2 (es)
EP (1) EP3370692B1 (es)
JP (1) JP6774435B2 (es)
KR (1) KR102628781B1 (es)
CN (1) CN107847430B (es)
AU (1) AU2016293004B2 (es)
BR (1) BR112018000592B1 (es)
CA (1) CA2992352C (es)
CL (1) CL2018000033A1 (es)
DK (1) DK3370692T3 (es)
EA (1) EA037085B1 (es)
ES (1) ES2949139T3 (es)
FI (1) FI3370692T3 (es)
HK (1) HK1253038A1 (es)
HU (1) HUE062108T2 (es)
IL (1) IL256883B (es)
LT (1) LT3370692T (es)
MA (1) MA43155A (es)
MX (1) MX2018000285A (es)
MY (1) MY194870A (es)
NZ (1) NZ738597A (es)
PH (1) PH12018500044A1 (es)
PL (1) PL3370692T3 (es)
PT (1) PT3370692T (es)
SA (1) SA518390689B1 (es)
WO (1) WO2017009351A1 (es)
ZA (1) ZA201708595B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180108811A (ko) * 2016-02-17 2018-10-04 이엔티 테크놀로지스 피티와이 리미티드 부비강 질환 및 장애의 치료를 위한 조성물 및 방법
GB2567285A (en) * 2017-08-07 2019-04-10 Suprapharm Cc Preparation for nasal-nasopharyngeal treatment
US20230120864A1 (en) 2020-03-12 2023-04-20 Sydney David Cullis-Hill Treatment for coronavirus infection and associated cytokine toxicity
CN111437270A (zh) * 2020-04-24 2020-07-24 瑞希(重庆)生物科技有限公司 一种卡拉胶鼻用即型凝胶喷雾剂及其制备方法
US11013687B1 (en) 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
WO2021253643A1 (zh) * 2020-06-18 2021-12-23 大连工业大学 硫酸化多糖在抗新型冠状病毒中的应用
CN111686125A (zh) * 2020-06-18 2020-09-22 大连工业大学 卡拉胶在抗新型冠状病毒中的应用
EP3939597A1 (en) * 2020-07-16 2022-01-19 Marinomed Biotech AG Antiviral pharmaceutical composition comprising a carrageenan component
US20230330013A1 (en) 2020-08-04 2023-10-19 Cosmosoft Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route
FR3113237B1 (fr) 2020-08-04 2023-06-09 Biopass Produit pour le traitement de maladies virales par voie nasale
EP3991561A1 (en) * 2020-10-28 2022-05-04 Vepidan ApS Antimicrobial disinfectant gel
GB202109888D0 (en) 2021-07-08 2021-08-25 Pollinner Ltd Nasal spray
KR20230094472A (ko) * 2021-12-21 2023-06-28 (주)메디코어 비강 세정제 조성물 및 그 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
DK2522365T3 (en) * 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US20080241271A1 (en) * 2006-11-08 2008-10-02 Roman Stephen B Foaming anti-adhesion composition
PL2101792T3 (pl) 2006-12-05 2010-11-30 Marinomed Biotechnologie Gmbh Zastosowanie karageniny do leczenia zakażeń rinowirusem
BRPI0815748B8 (pt) 2007-08-24 2021-05-25 Marinomed Biotechnologie Gmbh uso de iota-carragenina em uma quantidade antiviral eficaz
FR2926218B1 (fr) 2008-01-10 2010-08-13 Galderma Res & Dev Composition comprenant un retinoide et du peroxyde de benzoyle disperse.
WO2013049538A1 (en) 2011-09-30 2013-04-04 Mcneil-Ppc, Inc. Allergen nasal compositions

Also Published As

Publication number Publication date
HK1253038A1 (zh) 2019-06-06
FI3370692T3 (fi) 2023-06-16
EP3370692B1 (en) 2023-04-12
IL256883A (en) 2018-03-29
CA2992352C (en) 2023-06-27
ZA201708595B (en) 2021-06-30
SA518390689B1 (ar) 2021-07-17
NZ738597A (en) 2021-12-24
MX2018000285A (es) 2018-02-19
MA43155A (fr) 2018-09-12
IL256883B (en) 2021-07-29
PH12018500044A1 (en) 2018-07-23
US20190060358A1 (en) 2019-02-28
EA037085B1 (ru) 2021-02-04
PT3370692T (pt) 2023-07-18
MY194870A (en) 2022-12-21
JP6774435B2 (ja) 2020-10-21
BR112018000592A2 (pt) 2018-09-11
LT3370692T (lt) 2023-07-10
ES2949139T3 (es) 2023-09-25
US10660914B2 (en) 2020-05-26
AU2016293004A1 (en) 2018-01-18
CN107847430B (zh) 2021-02-02
HUE062108T2 (hu) 2023-09-28
JP2018523635A (ja) 2018-08-23
PL3370692T3 (pl) 2023-08-14
CN107847430A (zh) 2018-03-27
EP3370692A1 (en) 2018-09-12
EA201890196A1 (ru) 2018-06-29
BR112018000592B1 (pt) 2024-02-06
CA2992352A1 (en) 2017-01-19
AU2016293004B2 (en) 2021-05-06
WO2017009351A1 (en) 2017-01-19
KR20180054570A (ko) 2018-05-24
DK3370692T3 (da) 2023-06-26
KR102628781B1 (ko) 2024-01-24

Similar Documents

Publication Publication Date Title
CL2018000033A1 (es) Composición para destapar una nariz tapada que tiene actividad antiviral.
NI201400842A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas.
CL2020000739A1 (es) Agente prolongado de control de ectoparasito para animales.
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
CL2017002164A1 (es) Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
AR104212A1 (es) Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina, métodos y usos de las mismas
BR112019004496A2 (pt) estabilizantes de mastócitos para tratamento de hipercitocinemia e infecção viral
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2016044839A3 (en) Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016116403A8 (en) Polyurethaneurea solutions for compositions with active ingredients or fragrances
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
BR112018009425A2 (pt) novas formulações
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
CO2020002624A2 (es) Formulación de uso tópico para el control y la prevención de parásitos en animales
BR112017016278A2 (pt) agente preventivo e/ou terapêutico de doença imune
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
MX2018011539A (es) Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
SG10201908007UA (en) Respiratory infection treating agent
BR112015028334A2 (pt) agente e método para o tratamento de herpes
AR100850A1 (es) Composición farmacéutica que comprende desmopresina y un agente estabilizador
MX2019005383A (es) Formulaciones antimicrobianas para el tratamiento de infecciones veterinarias de pezuña.
AR110957A1 (es) Agente terapéutico oral para tiroides